Quantcast
Last updated on April 25, 2014 at 5:25 EDT

Latest H5N1 clinical trials Stories

2013-08-16 12:24:13

PHILADELPHIA, Aug. 16, 2013 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine. This is the second GSK intramuscular quadrivalent influenza vaccine approved by the FDA. GSK's Fluarix...

2013-08-05 12:28:43

- First broadening of influenza-strain protection to occur in more than 30 years PHILADELPHIA, Aug. 5, 2013 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] announced today it has received U.S. Food and Drug Administration (FDA) approval to start shipping 2013-2014 FLUARIX(®) QUADRIVALENT (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers. This is the first season that vaccines protecting against more than three strains of influenza (flu) will be...

2013-08-03 23:01:10

RnRMarketResearch.com adds Latest Report on “Research Report on Global and China Human Vaccine Industry, 2013-2017” to its store. Dallas, Texas (PRWEB) August 03, 2013 The research object of the report is human vaccines. According to different types and sources, vaccines can be divided into pathogenic protein vaccines, recombinant protein vaccines, immune protein vaccines and gene vaccines. In China, vaccines are generally divided into Vaccine I and Vaccine II. Vaccine I is offered...

2013-05-30 04:22:53

BEIJING, May 30, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced Sinovac's new drug application (NDA) for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. In terms of next steps for the NDA review process in China, the Beijing Drug Administration will conduct an on-site inspection on the circumstances of Sinovac's clinical trials and submit its on-site inspection...

2013-05-29 08:30:36

NEWARK, Del., May 29, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that a patent to increase influenza vaccine performance through the use of iBio's proprietary iBioModulator fusion protein technology has been allowed in China. The patent, which will issue from Chinese patent application No.: 200780008098.3, will further broaden the territories in which patent exclusivity has been secured for this novel technology. In the U.S., the technology is covered by issued U.S....

2013-05-22 08:27:27

PRINCETON, N.J., May 22, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the US Patent and Trademark Office granted patent 8,444,991 entitled "Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition." The new patent's claims encompass...

2013-05-02 12:28:42

Ready to Manufacture a Vaccine for the H7N9 Influenza Virus MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine. It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary,...

2013-04-18 10:04:12

All 3 configurations of adjuvant and route of administration exceeded the 3 CHMP criteria IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs),...

2013-04-11 08:29:37

PISCATAWAY, N.J., April 11, 2013 /PRNewswire/ -- This week the World Health Organization reported three cases in which humans were infected with Avian Influenza A (H7N9) Virus in China. These are the first reports of the H7N9 strain infecting humans. Currently, it is unclear whether or not the virus can be spread via human-to-human contact, however genetic sequences for the virus have been published, and the Center for Disease Control has reported the start of vaccine development for the...

2013-04-09 16:24:05

LONDON, April 9, 2013 /PRNewswire/ -- Bioradar UK Ltd and Replikins Ltd announced today that a new completely synthetic H7N9 Replikins Vaccine is ready for testing. The news comes on the heels of four new cases of avian flu (H7N9) reported in China, bringing the total to 28 cases, 8 of whom have died from the virus. The new vaccine is produced without any biological substances and will be used without adjuvants, similar to the H5N1 Synthetic Replikins Vaccine which was found effective (1)....